Functional inactivation of p53 induced by mutations or deletions accounts for near about 50% of human cancers around the world [9], mostly seen in cancers related to the breast, prostate, and cancers in which these mutations are connected with poor prognosis and enhanced chemo reluctance. The gene discussed is TP53; the disease is cancer.